Epilepsy genetics is shifting from the academic pursuit of gene discovery to a clinical discipline based on molecular diagnosis and stratified medicine. We consider the latest developments in epilepsy genetics and review how gene discovery in epilepsy is influencing the clinical classification of epilepsy and informing new therapeutic approaches and drug discovery.
INTRODUCTION
Epilepsy genetics can be conceptualized under two broad headings: monogenic epilepsy in which a single variant of large effect is considered causative and complex genetic epilepsy in which a presumed combinatorial effect of multiple susceptibility variants is thought to underlie the disease. Although advances in next-generation sequencing (NGS) have led to substantial progress in the discovery of genes for monogenic epilepsy, attempts to identify variants that confer susceptibility to complex epilepsy using genome-wide association study (GWAS) have identified few contributory variants [1] , most likely because of the small sample sizes of the epilepsy GWAS to date [2] . In contrast to the current state of the art for epilepsy GWAS, NGS-enabled discovery of the importance of de novo mutation in epileptic encephalopathy [3,4,5 & ], and neurodevelopmental disease more generally [6] , represents a fundamental scientific advance. NGS studies have revealed how mutations in the same gene can give rise to a spectrum of epilepsy phenotypes (or even different forms of neurodevelopmental disease) and have highlighted the genetic heterogeneity underlying some relatively well defined epilepsy phenotypes [7] . As analysis of epilepsy gene panels [8 & ] and clinical whole exome sequencing becomes mainstream, the diagnostic approach in epilepsy genetics is increasingly one that moves from genotype to phenotype. In this review, we consider the recent advances in epilepsy genetics and in particular how these discoveries are changing the conceptual boundaries between epilepsy phenotypes and the prospects for precision medicine and new drug discovery based on epilepsy gene discovery.
RECENT ADVANCES IN MONOGENIC EPILEPSY
Below, we consider the latest advances in gene discovery for monogenic epilepsy.
The extent of phenotypic variability associated with GABA receptor mutations is becoming apparent, with GABRA1 mutations originally reported in a family with dominantly inherited Juvenile Myoclonic Epilepsy now also described in severe infantile onset epileptic encephalopathies [9 
KEY POINTS
Next-generation sequencing has enabled rapid progress in gene discovery for epilepsy, and this has already led to material advances in clinical diagnosis and care.
Epilepsy genetics has implications for the classification of epilepsy, which will evolve with time and requires an agreed framework of terminology. This includes a need to understand the relationship between the genetic underpinnings of epilepsy and other neurodevelopmental diseases.
There is optimism that drug therapy for epilepsy can be targeted to the underlying genetic cause, but to date examples of precision medicine are mostly in gain-offunction mutations in ion-channel genes. This highlights a need to develop new approaches to drug discovery in epilepsy that address non-ion channel epilepsy genes and loss-of-function mutations.
Another fascinating development has been the association between epilepsy and genes involved in transcriptional regulation through chromatin remodeling. ]. It is perhaps surprising that genes involved in chromatin remodeling have been associated with such apparently well delineated clinical syndromes as intuitively, one might expect a large number of downstream genes to be disrupted and therefore the phenotypes to be broad and variable. In fact, chromatin remodeling genes appear to be highly selective in the genes that they regulate [40 & ]. As well as facilitating the discovery of new epilepsy genes, the ability of NGS to screen for genetic variants in multiple genes in parallel has revealed the potential for so-called blended phenotypespatients whose disorder might be explained by more than one large-effect genetic variant. Recently published cases of blended phenotypes in epilepsy include dominantly coinherited SLC20A2 and CHRNB2 mutations associated with familial generalized epilepsy with basal ganglia calcifications [41 & ]; a de novo GNAO1 mutation combined with a de novo HESX1 mutation associated with progressive encephalopathy with edema, hypsarrhythmia and optic atrophy syndrome [42 & ]; de-novo deletion of MEF2C with an inherited SCN1A variant associated with drug-resistant childhood-onset epilepsy [43 & ]; and a patient with 7q11.23 deletion (Williams syndrome) plus a de novo GABRA1 variant presenting with a severe drug-resistant epilepsy [44 & ]. Whether some patients with sudden unexpected death in epilepsy (SUDEP), who have been found to harbor an increased burden of de novo mutations at a population level, represent a multiallelic severe epilepsy phenotype remains to be determined [45 & ].
GENE DISCOVERY AND THE INTERNATIONAL LEAGUE AGAINST EPILEPSY CLASSIFICATION
The last ratified International League Against Epilepsy (ILAE) Classification of the Epilepsies was in 1989 [46] . Development of an updated classification for primarily clinical purposes, which acknowledges the scientific advances in our understanding of the causes of the epilepsies, has involved a wide engagement with the epilepsy community over a period of 7 years. This long iterative process has included publication of proposals for classification from the ILAE Commission for Classification and Terminology alongside commentary articles and online feedback [47 & ]. The process will be complete with the publication of two companion articles, one on the classification of seizure types and the other on the overall classification of the epilepsies in the journal Epilepsia in 2017.
One of the principal drivers for a new classification was the clinical imperative to consider cause at each of three levels of epilepsy classification. These levels are seizure type (generalized onset, focal onset and unknown onset), epilepsy type (generalized, focal, combined generalized and focal and unknown type) and epilepsy syndrome. The framework for the classification of epilepsies divides cause into six groups chosen for their treatment implications -structural, genetic, infectious, metabolic, immune and unknown. The concept of a genetic epilepsy is that it results directly from a known or presumed genetic mutation in which seizures are a core symptom of the disorder. In the new classification scheme, there are three ways in which an epilepsy may be classified as genetic. First, evidence for a genetic cause may be based solely on a family history whether or not the disorder has a known gene. Second, clinical research in populations with the same syndrome may suggest that a disorder is primarily genetic, for example twin studies in Juvenile Myoclonic Epilepsy [48] . Third, a pathogenic gene variant may have been reproducibly associated with an epilepsy phenotype. In the new ILAE classification of the epilepsies, 'genetic' will not equate to 'inherited' as de novo pathogenic gene variants are important particularly in severe infantile-onset disorders.
As new genes are associated with epilepsy, it is likely that the genetic disorders will be named after the gene. For example 'SCN8A encephalopathy' [49 & ] or 'GRIN2 encephalopathy' [17 & ]. Epilepsy genes are typically expressed widely in the central nervous system, and (as detailed above) pathogenic variants in these genes can produce diverse phenotypes including movement disorders, learning disability and autistic features, which may be more prominent and clinically relevant than the epilepsy [50 & ]. Currently, epilepsy genetics appears to be on the cusp of an epistemological crossroads -should these conditions be considered genetic epilepsies, or genetic developmental disorders in which epilepsy may (or may not) be a component of the symptom complex?
PRECISION MEDICINE IN EPILEPSY: HOPE VERSUS DATA
The importance of highly penetrant de novo mutation in epilepsy along with advances in our [51] has led to optimism that antiepileptic treatments could be targeted to a person's specific genetic diagnosis (precision medicine) [52 & ]. In this section, we discuss some of the studies that have established a proof-of-principle for precision medicine in epilepsy, but we also consider potential barriers to its wider implementation. In the discussion below, we narrowly define precision medicine as a specific drug therapy targeting an underlying genetic defect, rather than the use of genetics to inform a stratified treatment approach such as the use of the ketogenic diet in GLUT1 deficiency syndrome [53 & ], or prescription of stiripentol and avoidance of sodium channel blockers in
One of the first reports of a targeted precision therapy in epilepsy was the off-label use of quinidine in the treatment of a child with EIMFS secondary to a gain-of-function missense mutation in KCNT1 (Arg428Gln) [55] . Prior in-vitro studies had established that quinidine is a blocker of KCNT1 channels, suggesting that the drug might be a precision therapy in epilepsy associated with gain-of-function KCNT1 mutation. Subsequent treatment with quinidine resulted in a marked reduction in seizure frequency and improved psychomotor development.
Seizure outcomes following treatment with quinidine have since been reported for two additional epilepsy patients with KCNT1 mutation [56 & ]. The epilepsy phenotypes were severe nocturnal seizures with onset in childhood, and a second case of EIMFS, due to Tyr796His and Lys629Asn missense mutations, respectively. Both mutations resulted in a gain-of-function, and in both cases quinidine restored mutant function toward wild-type in vitro. However, although the patient with EIMFS had an 80% reduction in seizure frequency following treatment with quinidine, the other child with nocturnal seizures did not improve. The reason for the discordant clinical response to quinidine in these two cases despite similar in-vitro evidence for efficacy is not known and highlights the need to consider the functional impact of mutations within a more systems-wide context.
Other recent cases exemplifying the potential of precision medicine in epilepsy have been described for patients with de novo mutations in GRIN2A [57] and GRIN2D [18 & ] treated with NMDA receptor blockers, and in SCN8A-associated epilepsy treated with phenytoin [58 & ]. Thus, Pierson et al. reported a child with epileptic encephalopathy and severe cognitive impairment associated with a gain-of-function Leu812Met missense mutation in GRIN2A [57] . In-vitro analysis revealed the US Food and Drug Administration (FDA) approved NMDAR blocker memantine inhibited GluN2A-Leu812Met-containing NMDARs and off-label treatment with oral memantine led to a reduction in the child's seizure burden. Li et al. [ 18 & ] subsequently reported two unrelated children with epileptic encephalopathy associated with gain-of-function mutations in GRIN2D. Here again, FDA-approved drugs that act as NMDAR blockers were evaluated in vitro, and subsequently both children were treated off-label with oral memantine with a reported 'mild to moderate' improvement in seizure burden. Boerma et al. [58 & ] reported four patients with severe epilepsy associated with putative gain-of-function SCN8A missense mutations in which seizure control was obtained with the sodium channel blocker phenytoin.
Although these cases illustrate the principles of precision medicine in epilepsy, in each of the examples described above the epilepsy resulted from a putative gain-of-function mutation. However, substantial evidence implicates protein loss-of-function and haploinsufficiency as a key mechanism of both epileptic encephalopathy and monogenic neurodevelopmental disease more broadly. Examples of precision medicine in epilepsy in which the approach has been to increase the activity of the wild-type allele to compensate for protein loss-offunction have been relatively few. To date, the only example of precision medicine targeting a loss-offunction mutation is a report of improvement of seizure frequency with the KCNQ2/KCNQ3 agonist retigabine in a number of patients with neonatalonset epileptic encephalopathy associated with KCNQ2 mutation [59 & ]. With the field still in its infancy, it is probably too early to tell if the paucity of reports of precision medicine in loss-of-function mutation reflects a more challenging pharmacological environment related to developing protein activators compared with blockers.
A further observation from the published examples of precision medicine in epilepsy is that so far all the cases resulted from mutation in an ionchannel subunit gene. To date, with the exception of the use of everolimus in tuberous sclerosis [60 && ], there are no reported examples of precision medicine targeting a monogenic epilepsy arising from mutation in the growing list of non-ion channel epilepsy genes such as LGI1, STXBP1, PCDH19, TCF4, CDKL5 and others. Given that many of these proteins have not been traditional targets for drug development, and their functional role in epilepsy is poorly understood, the development of precision therapies for epilepsy resulting from mutation in non-ion channel genes may advance slowly. This highlights the need for new approaches to drug discovery for monogenic epilepsy. One proposal has been to develop systems for the experimental high-throughput screening of compounds such as the use of stem cell models of epilepsy ('epilepsy in a dish') [52 & ]. However, with potentially many thousands of causal variants for epilepsy in hundreds of different genes [2] , and thousands of known drugs (www.drugbank.ca/stats), there are potentially tens of millions of drug-disease pairings, making the exhaustive experimental screening of all known drugs for all epilepsy variants unfeasible. This combinatorial problem will require, at least in part, a computational solution.
One approach to developing a computational framework for new drug discovery and drug screening makes use of a systems perspective of disease. Here, a disease is viewed in terms of its molecular drivers arising from the interaction of sets of genes in regulatory networks [61] . In epilepsy, network analyses have revealed that many different genes for epileptic encephalopathy interact in gene regulatory networks [62 Critically, the computational screen was conducted entirely independently of valproate's known mechanism of action or role in epilepsy, and was based solely on an unsupervised analysis of disease-related and drug-related gene expression profiles. Such studies highlight the potential of network-based drug discovery as a novel and efficient strategy for new drug discovery in epilepsy. Moreover, since network approaches target sets of coregulated genes, they may also offer an approach to developing therapies for epilepsies arising from the coordinated dysregulation of sets of genes due to mutation in chromatin remodeling genes or other gene regulatory sequences, or arising from aberrant homeostatic neuronal responses to mutation.
CONCLUSION
We live in an unprecedented era of epilepsy gene discovery. Epilepsy genetics is moving rapidly from gene discovery to clinical practice, and these discoveries highlight a plethora of potential new mechanisms for epilepsy. Whether these mechanisms will converge around common pathways or each require the development of a specific targeted therapy is currently unclear, but there is genuine optimism that the era of NGS-enabled gene discovery will lead to advances in the care of people with epilepsy.
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